At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 36 enrolled
Drug / intervention
Omega-3 fish oil lipid emulsiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Use of Omegaven for Parenteral Nutrition Associated Liver Disease
In Brief
A Phase 3 clinical trial evaluating Omega-3 fish oil lipid emulsion for Cholestasis. Completed, enrolled 36 participants across 1 site.
Detailed Summary
Use of a fish oil emulsion to decrease liver disease due to long term intravenous nutrition.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCholestasis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2010
Enrollment StartOct 2010
Primary CompletionNov 2018
Study CompletionJan 2019
TodayJul 2026
First PostedSep 2, 2010
Enrollment StartOct 20, 2010
Primary CompletionNov 30, 2018
Study CompletionJan 15, 2019
TodayJul 2, 2026
Enrollment to primary: 8.1 yearsPosted 15.8 years ago
Interventions
Omega-3 fish oil lipid emulsiondrug
daily intravenous administration of Omegaven fish oil emulsion